CSIMarket
 
Decibel Therapeutics Inc   (DBTX)
Other Ticker:  
 
 
Price: $4.9100 $-0.04 -0.808%
Day's High: $5.11 Week Perf: -1.6 %
Day's Low: $ 4.90 30 Day Perf: -4.29 %
Volume (M): 1,261 52 Wk High: $ 5.26
Volume (M$): $ 6,192 52 Wk Avg: $3.84
Open: $4.92 52 Wk Low: $2.41



 Market Capitalization (Millions $) 123
 Shares Outstanding (Millions) 25
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -63
 Cash Flow (TTM) (Millions $) -17
 Capital Exp. (TTM) (Millions $) 1

Decibel Therapeutics Inc
Decibel Therapeutics Inc is a biotechnology company based in Boston, Massachusetts. The company focuses on developing therapies for the treatment of hearing and balance disorders. Their goal is to restore and preserve hearing by targeting the underlying causes of these conditions, such as sensorineural hearing loss.

Decibel Therapeutics utilizes a multidisciplinary approach that combines genetics, bioinformatics, and experimental biology to identify potential drug targets. They have a robust pipeline that includes both small molecule drugs and gene therapies. The company's approach is centered around understanding the biology of the inner ear and developing targeted interventions to improve hearing function.

Decibel Therapeutics collaborates with academic institutions, pharmaceutical companies, and patient advocacy groups to advance their research. Their ultimate objective is to positively impact the lives of individuals affected by hearing and balance disorders.


   Company Address: 1325 Boylston Street Boston 2215 MA
   Company Phone Number: 370-8701   Stock Exchange / Ticker: NASDAQ DBTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Decibel Therapeutics Inc

Decibel Therapeutics Inc's Financials Revealed: Operating Deficit Grows Amidst Emerging Growth


Introduction
Decibel Therapeutics Inc, an emerging growth corporation in the Major Pharmaceutical Preparations industry, is set to report its financial results from April to June 30, 2023. Despite shareholders not expecting significant changes in the company, there are concerns over the operating deficit that has grown over the past year. This article aims to shed light on the financial situation at Decibel Therapeutics Inc and provide a comparison to previous performance.
Operating Deficit and Emerging Growth
During the April to June 30, 2023 reporting cycle, Decibel Therapeutics Inc's operating deficit stood at $-19.041 million. This figure is of concern to stockholders, as it represents a noticeable decline from the operating deficit of $-17.103 million reported in the same period the previous year. It is worth noting that the company has not announced its revenue yet, but a comparison to past performance offers some insight into the current situation.

Decibel Therapeutics Inc

Decibel Therapeutics Inc's Astonishing Turnaround: Unprecedented Decrease in Operating Deficit Signals Promising Future

Decibel Therapeutics Inc is a pharmaceutical company that was founded in 2015 with a commitment to discovering and developing transformative medicines to treat hearing and balance disorders. The company's research focuses on hearing loss, which is a widespread problem worldwide, affecting approximately 466 million people globally. Decibel Therapeutics' innovative approach aims to address the underlying molecular and cellular mechanisms of hearing and balance disorders to develop effective treatments.
As of the first quarter of 2023, Decibel Therapeutics has been closely watched by sector veterans as they interpret the company's performance. The company has reported an operating deficit of $-14.121 million, indicating that there has been no revenue yet for the respective January to March 31, 2023 quarter. However, it is important to note that there has been a reduction in the operating deficit, as compared to the previous quarter.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com